Insulin icodec is under clinical development by Novo Nordisk and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Insulin icodec’s likelihood of approval (LoA) and phase transition for Type 2 Diabetes took place on 10 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Insulin icodec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Insulin icodec overview
Insulin icodec (LAI-287) is under development for the treatment of type 1 and type 2 diabetes. It is administered subcutaneously. LAI-287 is a long-acting basal insulin analogue with potential for once weekly dosing. The drug candidate targets insulin receptor.
Novo Nordisk overview
Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Quick View Insulin icodec LOA Data
|Highest Development Stage|